MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » Aria completes $31m Series B for its pulmonary hypertension treatment device

Aria completes $31m Series B for its pulmonary hypertension treatment device

By

Aria CVPulmonary arterial hypertension (PAH) treatment developer Aria CV announced today that it completed a $31 million Series B financing round.

The proceeds from the round, led by private equity and venture investor Xeraya Capital, are earmarked for funding St. Paul, Minn.–based Aria CV’s first U.S. clinical study.

Aria CV’s early feasibility investigational study is set out to evaluate long-term implants of the company’s pulmonary hypertension (PH) system for people with PAH. Earlier this month, Aria CV won breakthrough device designation from the FDA for its PH system.

The PH system is designed to restore the benefits of a healthy, elastic pulmonary artery. The restoration should lead to reduced cardiac workload and enhance blood flow, potentially improving both the duration and quality of life.

“Aria CV is now well-positioned to drive our clinical research forward,” Aria CV president & CEO Dan Gladney said in a news release. “We are grateful for this validation by our investors and remain committed to bringing this innovative treatment option to PAH patients.”

Other participants in the funding round included Longview Ventures, Catalyst Health Ventures, BioStar Ventures, Cedar Point Capital, Frontcourt Group and three more unnamed strategic investors. As a result, Jason Rushton (Xeraya Capital), Darshana Zaveri (Catalyst Health Ventures), Maria Berkman (Longview Ventures) and Renee Masi (BioStar Ventures) are set to join Aria CV’s board of directors.

In case you missed it

RSS From Medical Design & Outsourcing

  • Philips updates on testing results for recalled ventilators
    Royal Philips (NYSE:PHG) says only a small portion of returned respiratory devices displayed the sound abatement foam degradation that sparked a massive recall. Repeated ozone cleaning may have made the problem worse. Those were some of the major takeaways from an update Philips provided today on a comprehensive test and research program it implemented after its… […]
  • ResMed names Lucile Blaise as new Sleep & Respiratory Care leader
    Lucile Blaise will be the new president of ResMed’s Sleep & Respiratory Care business starting July 1, ResMed (NYSE: RMD) said today. She replaces Jim Hollingshead, who became president and CEO of Insulet (Nasdaq:PODD) on June 1. ResMed President and COO Rob Douglas is serving as interim president of the Sleep & Respiratory Care during… […]
  • Cardinal Health starts Zipline drone deliveries of drugs and medical supplies
    Cardinal Health (NYSE: CAH) today started air delivery of pharmaceutical products and medical supplies via Zipline drone in North Carolina. San Francisco-based Zipline won FAA Part 135 air carrier certification for the long-range flights earlier this month. The company flew its first commercial deliveries on June 22 with an initial 16-nautical-mile flight. The flights starting… […]
  • How medical device companies are responding to abortion bans
    Days after the U.S. Supreme Court’s decision to overturn Roe v. Wade’s protection of abortion rights, medical device companies are among those reassuring workers about healthcare access. Corporate communications to employees and the public at large come as trigger laws in nearly half of the states outlaw abortion immediately. Some medtech companies are not using… […]
  • Boston Centerless opens manufacturing plant in Indiana
    Boston Centerless announced today that it opened a second manufacturing plant in Fort Wayne, Indiana. Woburn, Massachusetts-based Boston Centerless said in a news release that the latest expansion for the supplier of precision ground bar materials for close tolerance CNC Swiss machining applications represents continued robust growth in key market segments in the Midwest and… […]
  • Dymax strikes new partnership with Quantum Systems
    Rapid curing materials and equipment manufacturer Dymax today announced a new sales partnership with Quantum Systems. Torrington, Connecticut-based Dymax said in a news release that Quantum, with its offices in Arizona as well as Sonora and Baja, Mexico, will focus its efforts on promoting and supporting the sales of Dymax light-curing solutions to the medical,… […]
  • Researchers develop wearable robotic exomuscle system
    ETH Zurich researchers have redefined the muscle shirt. Marie Georgarakis, a former doctoral student at ETH Zurich’s Sensory Motor Systems Lab, is the creator of the Myoshirt, a wearable, textile robotic device that helps users lift their arms and reach. A motorized cable works like an artificial tendon, directed by sensors and an algorithm to… […]
  • They said it at DeviceTalks Boston
    Medtech insiders convened at DeviceTalks Boston 2022 in May to discuss device design, innovation and trends shaping the industry now and in the years and decades ahead. Here are some of the most quotable insights from panelists and speakers at our live event. And make sure to save the date — and save your seat… […]
  • Summer health technology program brings diverse group of interns to Silicon Valley
    Diversity by Doing HealthTech (DxD) is holding a Summer Innovation and Exploration Series for college student interns from underrepresented groups. The series is on its second day today at Fogarty Innovation and Stanford Byers Center for Biodesign — the two organizations that jointly formed and support DxD. The event debuted last year in an online… […]
  • Clippard releases new series of isolation valves
    Clippard (Cincinnati) has Its Clippard NIV Series media isolation valve — a solenoid-operated device using a flexible diaphragm to isolate the actuation mechanism from the fluid path. Media isolation valves find everyday use in a wide variety of applications. Think uses that require precise, repeatable dispensing of media for analytical instrumentation. Clippard says media isolation… […]
  • Another Medtronic HVAD recall is serious
    A year after Medtronic ceded the LVAD market to Abbott, it has yet another Class I recall involving HeartWare Ventricular Assist Device pumps still implanted in patients. The FDA today designated a Medtronic recall involving the HVADs as Class I, the most serious level. It’s the second Class I recall designation for the HVADs this… […]